Bilgir Ferda, Bilgir Oktay, Akan Ozden Yildirim, Demir Ismail
. Katip Celebi University Ataturk Training and Research Hospital, Department of Allergy and Immunology, Izmir, Turkey.
. Health Sciences University Bozyaka Training and Research Hospital, Department of Internal Medicine, Bozyaka, Izmir, Turkey.
Rev Assoc Med Bras (1992). 2020 Aug;66(8):1057-1061. doi: 10.1590/1806-9282.66.8.1057.
This study aimed to investigate the effect of propylthiouracil treatment on adhesion molecules in patients with subclinical hyperthyroidism.
In this study, a total of 168 patients diagnosed with subclinical hyperthyroidism were treated with propylthiouracil for one year. The levels of adhesion molecules, consisting of sICAM-1, sVCAM-1, and sE-Selectin, before and after the treatment were measured and compared. These results were compared with the levels of 148 healthy controls who received a placebo.
sICAM-1 levels were significantly higher in subclinical hyperthyroidism patients than in healthy controls (*pa=0.000). sICAM-1 levels were significantly decreased after the treatment (**pb=0.000). Despite this decrease in patients with subclinical hyperthyroidism, it did not decrease to the level of the control group. sVCAM-1 did not change before and after propylthiouracil treatment. The level of sE-selectin was similar to that of the pretreatment control group, but it did not have statistical significance, although it increased after the treatment (**pb=0.004).
The sICAM level was significantly higher than the pretreatment values and decreased after the propylthiouracil treatment. However, further studies are needed to reduce the risk of atherosclerosis and cancer in patients with subclinical hyperthyroidism.
本研究旨在探讨丙硫氧嘧啶治疗对亚临床甲状腺功能亢进患者黏附分子的影响。
本研究中,共有168例诊断为亚临床甲状腺功能亢进的患者接受丙硫氧嘧啶治疗1年。测量并比较治疗前后由可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)和可溶性E-选择素组成的黏附分子水平。将这些结果与148例接受安慰剂的健康对照者的水平进行比较。
亚临床甲状腺功能亢进患者的sICAM-1水平显著高于健康对照者(pa = 0.000)。治疗后sICAM-1水平显著降低(pb = 0.000)。尽管亚临床甲状腺功能亢进患者的sICAM-1水平有所下降,但并未降至对照组水平。丙硫氧嘧啶治疗前后sVCAM-1水平未发生变化。sE-选择素水平与治疗前对照组相似,尽管治疗后有所升高(pb = 0.004),但无统计学意义。
sICAM水平显著高于治疗前值,丙硫氧嘧啶治疗后降低。然而,需要进一步研究以降低亚临床甲状腺功能亢进患者动脉粥样硬化和癌症的风险。